Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain inhibitory neurons (46 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 29 | 0.91 |
| pathways Reactome | 2 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 14651
Sealed predictions
- FBXL16 in dopamine neurons, braak-0.28 (p 0.461) → -0.24 (p 0.535)receipt 14658
Swarm cases
receipt 14658: FBXL16 in dopamine neurons, braak
- power
- full sample -0.19 (p 0.444, n 18), 95% CI -0.60 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.444, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.26 (p 0.302, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.08, sign flips 0; without severely affected donors -0.19 (p 0.444, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FBXL16 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts